Rita L. McGill
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rita L. McGill has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Arlene B. Chapman
3 shared publications- Arlene B. Chapman
Division of Nephrology, University of Chicago School of Medicine, Chicago, Illinois
2 shared publications Dana C. Miskulin
2 shared publicationsJennifer L. Ennis
Laboratory Corporation of America, Chicago, Illinois, USA
2 shared publications- Louis G. Baeseman
Section of Nephrology, Department of Medicine, University of Chicago, Chicago, IL USA
2 shared publications - Samantha Gunning
Section of Nephrology, University of Chicago, Chicago, Illinois
2 shared publications
Latest Publications
- 29 September 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
Serum Uromodulin in Dialysis Patients
Was not provided for this article.
- 29 September 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
Serum Uromodulin in Dialysis Patients
Was not provided for this article.
- 31 July 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (10) , 1762-1771
Peritoneal Dialysis Outcomes in Autosomal Dominant Polycystic Kidney Disease
Key Points: Peritoneal dialysis can be used successfully in patients with autosomal dominant polycystic kidney disease. Compared with days receiving hemodialysis, peritoneal dialysis days were associated with better patient survival, which has increased over time. Compared with hemodialysis days, peritoneal dialysis days were associated with a higher rate of kidney transplant, which has increased over time. Background: Peritoneal dialysis (PD) is a form of home dialysis that is underutilized in the United States. Patients with autosomal dominant polycystic kidney disease (ADPKD) are frequently good PD candidates who are often young and have few comorbid conditions. However, clinicians may be hesitant to recommend PD to patients with ADPKD because of perceived concerns for mechanical complications and technique failure. Little is known about outcomes of patients with ADPKD undergoing PD in the United States. Methods: A retrospective cohort of patients with ESKD 30 years and older registered in the United States Renal Data System with a diagnosis of cystic kidney disease from January 1, 2000, to December 31, 2021, was followed until death or January 1, 2023, whichever occurred first. A time-dependent variable for kidney treatment modality was created, allowing calculation of hazard ratios (HRs) and confidence intervals (CIs) on the basis of time proximity of PD exposure to death and kidney transplantation, compared with hemodialysis. Cox models were adjusted for age, sex, race, body mass index, serum albumin, hemoglobin, year of incident ESKD, insurance status, and comorbid conditions at the time of inclusion. Results: Among 53,651 incident ADPKD patients with ESKD, 26% received some PD. Over a median follow-up of 75 months, 26,375 (49%) of the patients received kidney transplants and 23,427 (44%) died. PD exposure was more likely among patients with ADPKD who were younger, were female, and had lower burden of comorbid diseases. In the adjusted models, PD was associated with lower mortality (HR, 0.84; 95% CI, 0.80 to 0.88, P < 0.001) and higher likelihood of transplant (HR, 1.12; 95% CI, 1.08 to 1.16; P < 0.001) compared with hemodialysis. The associations with lower mortality and higher transplantation became progressively more prominent with each passing year. Conclusions: These data indicate that PD is a safe and advantageous dialysis option for patients with ADPKD that is associated with longer patient survival and opportunities for kidney transplant.
- 31 July 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (10) , 1762-1771
Peritoneal Dialysis Outcomes in Autosomal Dominant Polycystic Kidney Disease
Key Points: Peritoneal dialysis can be used successfully in patients with autosomal dominant polycystic kidney disease. Compared with days receiving hemodialysis, peritoneal dialysis days were associated with better patient survival, which has increased over time. Compared with hemodialysis days, peritoneal dialysis days were associated with a higher rate of kidney transplant, which has increased over time. Background: Peritoneal dialysis (PD) is a form of home dialysis that is underutilized in the United States. Patients with autosomal dominant polycystic kidney disease (ADPKD) are frequently good PD candidates who are often young and have few comorbid conditions. However, clinicians may be hesitant to recommend PD to patients with ADPKD because of perceived concerns for mechanical complications and technique failure. Little is known about outcomes of patients with ADPKD undergoing PD in the United States. Methods: A retrospective cohort of patients with ESKD 30 years and older registered in the United States Renal Data System with a diagnosis of cystic kidney disease from January 1, 2000, to December 31, 2021, was followed until death or January 1, 2023, whichever occurred first. A time-dependent variable for kidney treatment modality was created, allowing calculation of hazard ratios (HRs) and confidence intervals (CIs) on the basis of time proximity of PD exposure to death and kidney transplantation, compared with hemodialysis. Cox models were adjusted for age, sex, race, body mass index, serum albumin, hemoglobin, year of incident ESKD, insurance status, and comorbid conditions at the time of inclusion. Results: Among 53,651 incident ADPKD patients with ESKD, 26% received some PD. Over a median follow-up of 75 months, 26,375 (49%) of the patients received kidney transplants and 23,427 (44%) died. PD exposure was more likely among patients with ADPKD who were younger, were female, and had lower burden of comorbid diseases. In the adjusted models, PD was associated with lower mortality (HR, 0.84; 95% CI, 0.80 to 0.88, P < 0.001) and higher likelihood of transplant (HR, 1.12; 95% CI, 1.08 to 1.16; P < 0.001) compared with hemodialysis. The associations with lower mortality and higher transplantation became progressively more prominent with each passing year. Conclusions: These data indicate that PD is a safe and advantageous dialysis option for patients with ADPKD that is associated with longer patient survival and opportunities for kidney transplant.
- 1 July 2026
- Published by SAGE Publications in The Journal of Vascular Access
- Vol. 27 (6) , 2584-2591
Clinical significance of maturing vascular access for incident hemodialysis patients
Background: Reliable vascular access is required for hemodialysis (HD). Central venous catheters (CVC) can be used immediately, but are traditionally associated with increased mortality compared to arteriovenous fistulas or grafts (AVF/AVG). Immature fistulas or grafts may or may not become usable; their impact on long-term mortality or transplant has not been defined. Methods: Adult incident HD patients entering the United States Renal Data System between 1/2018 and 12/2019 were identified, and included if still on HD at day 90. Initial dialysis accesses were categorized as mature AVF/AVG, CVC-only, or CVC with an fistula or graft that was not ready for use (CVC-plus). Cox models were used to examine the associations between access type and patient mortality, and logistic models for kidney transplant waitlist appearance, using propensity-matched samples. CVC-plus was the reference group for all models. Results: Among 214,673 patients, 66% had CVC-only, 15% CVC-plus, and 19% AVF/AVG. Over median follow up of 30 months, 45% died and 5% received kidney transplants. Compared to patients with CVC-plus, having CVC-only was associated with increased death (HR = 1.31, 95% CI = 1.29–1.35, p < 0.001) but similar rates of kidney transplantation (HR = 1.01, 95% CI = 0.97–1.14, p = 0.20), despite more waitlisting. Having AVF/AVG was associated with decreased death (HR = 0.81, 95% CI = 0.79–0.83) and increased transplantation (HR = 1.39, 95% CI = 1.30–1.50), p < 0.001 for both. Conclusions: Initiating HD with CVC-plus was advantageous compared to CVC-only, but outcomes were inferior to those of patients initiating HD with mature AVF/AVG.
- 1 July 2026
- Published by SAGE Publications in The Journal of Vascular Access
- Vol. 27 (6) , 2584-2591
Clinical significance of maturing vascular access for incident hemodialysis patients
Background: Reliable vascular access is required for hemodialysis (HD). Central venous catheters (CVC) can be used immediately, but are traditionally associated with increased mortality compared to arteriovenous fistulas or grafts (AVF/AVG). Immature fistulas or grafts may or may not become usable; their impact on long-term mortality or transplant has not been defined. Methods: Adult incident HD patients entering the United States Renal Data System between 1/2018 and 12/2019 were identified, and included if still on HD at day 90. Initial dialysis accesses were categorized as mature AVF/AVG, CVC-only, or CVC with an fistula or graft that was not ready for use (CVC-plus). Cox models were used to examine the associations between access type and patient mortality, and logistic models for kidney transplant waitlist appearance, using propensity-matched samples. CVC-plus was the reference group for all models. Results: Among 214,673 patients, 66% had CVC-only, 15% CVC-plus, and 19% AVF/AVG. Over median follow up of 30 months, 45% died and 5% received kidney transplants. Compared to patients with CVC-plus, having CVC-only was associated with increased death (HR = 1.31, 95% CI = 1.29–1.35, p < 0.001) but similar rates of kidney transplantation (HR = 1.01, 95% CI = 0.97–1.14, p = 0.20), despite more waitlisting. Having AVF/AVG was associated with decreased death (HR = 0.81, 95% CI = 0.79–0.83) and increased transplantation (HR = 1.39, 95% CI = 1.30–1.50), p < 0.001 for both. Conclusions: Initiating HD with CVC-plus was advantageous compared to CVC-only, but outcomes were inferior to those of patients initiating HD with mature AVF/AVG.
- 19 September 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (1) , 108-117
Hypothermic Perfusion Mitigates Extended Cold Ischemia Time in Kidney Transplantation
Key Points: Compared with ≤ 12 hours of static cold storage, hypothermic machine perfusion up to 36 hours did not increase death-censored graft failure. Hypothermic machine perfusion reduced delayed graft function for kidneys with ≤36 hours of cold ischemia time. When cold ischemia time exceeded 36 hours, hypothermic machine perfusion no longer affected outcomes. Background: Extended cold ischemia time (CIT) is associated with higher incidences of delayed graft function (DGF) and graft failure. Kidneys on hypothermic machine perfusion (HMP) perform better than comparable kidneys in static cold storage (SCS). This study aimed to determine whether hypothermic perfusion was associated with lowering the deleterious effects of extended CIT. Methods: Data from the United Network of Organ Sharing database were examined to identify adult first-time, kidney-only recipients from 2005 to 2022. Multivariable models for death-censored graft failure (dcGF), uncensored graft failure, DGF, and patient mortality were constructed and adjusted for donor, recipient, and transplant factors. Kidneys with ≤12 hours SCS, an accepted standard for optimal transplantation, served as the reference group for each model. Results: Among 120,438 allografts, 63% were in SCS and 37% were preserved with hypothermic perfusion. DcGF was higher in a dose-dependent fashion as CIT increased. Kidneys on HMP for ≤24 hours had less dcGF than reference (≤12 hours in SCS) kidneys. Perfusion for 24–36 hours did not differ from reference. After 36 hours, all kidneys had higher dcGF, regardless of the storage method. HMP lowered the incidence of DGF at every level of CIT. Conclusions: HMP is an effective strategy for lowering the negative effect of prolonged CIT, providing transplant teams with greater flexibility to optimize donor and recipient logistics, without compromising long-term graft outcomes.
- 19 September 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (1) , 108-117
Hypothermic Perfusion Mitigates Extended Cold Ischemia Time in Kidney Transplantation
Key Points: Compared with ≤ 12 hours of static cold storage, hypothermic machine perfusion up to 36 hours did not increase death-censored graft failure. Hypothermic machine perfusion reduced delayed graft function for kidneys with ≤36 hours of cold ischemia time. When cold ischemia time exceeded 36 hours, hypothermic machine perfusion no longer affected outcomes. Background: Extended cold ischemia time (CIT) is associated with higher incidences of delayed graft function (DGF) and graft failure. Kidneys on hypothermic machine perfusion (HMP) perform better than comparable kidneys in static cold storage (SCS). This study aimed to determine whether hypothermic perfusion was associated with lowering the deleterious effects of extended CIT. Methods: Data from the United Network of Organ Sharing database were examined to identify adult first-time, kidney-only recipients from 2005 to 2022. Multivariable models for death-censored graft failure (dcGF), uncensored graft failure, DGF, and patient mortality were constructed and adjusted for donor, recipient, and transplant factors. Kidneys with ≤12 hours SCS, an accepted standard for optimal transplantation, served as the reference group for each model. Results: Among 120,438 allografts, 63% were in SCS and 37% were preserved with hypothermic perfusion. DcGF was higher in a dose-dependent fashion as CIT increased. Kidneys on HMP for ≤24 hours had less dcGF than reference (≤12 hours in SCS) kidneys. Perfusion for 24–36 hours did not differ from reference. After 36 hours, all kidneys had higher dcGF, regardless of the storage method. HMP lowered the incidence of DGF at every level of CIT. Conclusions: HMP is an effective strategy for lowering the negative effect of prolonged CIT, providing transplant teams with greater flexibility to optimize donor and recipient logistics, without compromising long-term graft outcomes.
- Open Access
- 8 August 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (12) , 2064-2067
Should Kidney Transplantation be Offered to Patients with Body Mass Index >40?: CON
- 8 August 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (12) , 2064-2067
Open AccessShould Kidney Transplantation be Offered to Patients with Body Mass Index >40?: CON
- Open Access
- 16 June 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (8) , 1415-1421
Transitional Care Units in the United States: A Model for Improving Dialysis Care
ESKD incidence rates are increasing, and mortality rates remain high. Fewer than 15% of patients use home dialysis modalities or receive preemptive kidney transplants. To address these shortcomings, executive order 13,879 (the Advancing American Kidney Health Initiative) directs the Centers for Medicare & Medicaid Services to encourage home dialysis and increase access to kidney transplants. Transitional care units (TCUs) have the potential to promote these goals by filling the gaps in care. TCUs are outpatient dialysis units for patients initiating dialysis with little or no predialysis care that provides education, facilitates smooth transitions to home or in-center dialysis, and expedites referrals to transplant clinics. TCUs offer patient-centered education, enhanced case management, and emotional support. This can improve vascular access outcomes, home dialysis utilization, and transplant referral rates. TCUs potentially address barriers to home dialysis and ideally compensate for inadequate pre-ESKD care. We performed a narrative review of several studies concerning the effect of TCUs on home dialysis utilization and patient outcomes. Eight primary studies from the United States, Canada, and the United Kingdom were reviewed, with about 7400 patients from several health and payer systems. We focused on TCU programs representing multiple payer systems, variable cohort selection criteria, and manuscripts that addressed Centers for Medicare & Medicaid Services quality measures and/or patient-centered outcomes. We call attention to the small numbers of TCUs in the United States and suggest that expansion of TCU's could benefit patients, particularly those who start dialysis under urgent conditions, which could promote equity within the ESKD population.
- 16 June 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (8) , 1415-1421
Open AccessTransitional Care Units in the United States: A Model for Improving Dialysis Care
ESKD incidence rates are increasing, and mortality rates remain high. Fewer than 15% of patients use home dialysis modalities or receive preemptive kidney transplants. To address these shortcomings, executive order 13,879 (the Advancing American Kidney Health Initiative) directs the Centers for Medicare & Medicaid Services to encourage home dialysis and increase access to kidney transplants. Transitional care units (TCUs) have the potential to promote these goals by filling the gaps in care. TCUs are outpatient dialysis units for patients initiating dialysis with little or no predialysis care that provides education, facilitates smooth transitions to home or in-center dialysis, and expedites referrals to transplant clinics. TCUs offer patient-centered education, enhanced case management, and emotional support. This can improve vascular access outcomes, home dialysis utilization, and transplant referral rates. TCUs potentially address barriers to home dialysis and ideally compensate for inadequate pre-ESKD care. We performed a narrative review of several studies concerning the effect of TCUs on home dialysis utilization and patient outcomes. Eight primary studies from the United States, Canada, and the United Kingdom were reviewed, with about 7400 patients from several health and payer systems. We focused on TCU programs representing multiple payer systems, variable cohort selection criteria, and manuscripts that addressed Centers for Medicare & Medicaid Services quality measures and/or patient-centered outcomes. We call attention to the small numbers of TCUs in the United States and suggest that expansion of TCU's could benefit patients, particularly those who start dialysis under urgent conditions, which could promote equity within the ESKD population.
- 28 January 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (4) , 563-572
Effect of Race on Transplantation in Autosomal Dominant Polycystic Kidney Disease
Key Points: Despite overall superior outcomes, transplant outcomes of patients with autosomal dominant polycystic kidney disease are heavily influenced by race. Access to living donor and preemptive transplantation partly explains these racial disparities. Favorable Expected Post-Transplant Survival scores suggest that promoting equity would result in improved survival for patients with ADPKD. Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic cause of ESKD and occurs without racial predilection. In general, non-White patients with ESKD have less access to transplantation, especially living donor transplantation. We examined long-term outcomes of patients with ADPKD-ESKD by self-reported race, with attention to the trajectory of Estimated Post-Transplant Survival (EPTS) scores over time. Methods: United Network for Organ Sharing Standard Transplant Analysis and Research files were used to identify 32,611 ADPKD transplant recipients between January 2000 and December 2022. EPTS scores were calculated from the date of waitlisting until transplantation occurred. Cumulative incidences of living and deceased transplantation were calculated and plotted. Cox models were made for graft failure and death, and a subdistribution hazards model for graft failure accounted for death as a competing outcome, with adjustment for patient, donor, and transplant factors. Results: Compared with White patients with ADPKD, all other groups had more dialysis years, more delayed graft function, and fewer living and preemptive transplants; mean EPTS scores were lower in Black and Hispanic patients at each time point on the waitlist. However, EPTS scores at the time of transplant was less likely to be <20% in Black and Hispanic patients because of longer waiting time. Black patients had a significantly higher risk of graft failure with death as competing risk compared with White patients. Asian and Hispanic patients had similar graft survivals but better patient survival compared with White patients. Conclusions: Waitlist experience, allograft quality, and post-transplant outcomes of patients with ADPKD are influenced by patient race.
- 28 January 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (4) , 563-572
Effect of Race on Transplantation in Autosomal Dominant Polycystic Kidney Disease
Key Points: Despite overall superior outcomes, transplant outcomes of patients with autosomal dominant polycystic kidney disease are heavily influenced by race. Access to living donor and preemptive transplantation partly explains these racial disparities. Favorable Expected Post-Transplant Survival scores suggest that promoting equity would result in improved survival for patients with ADPKD. Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic cause of ESKD and occurs without racial predilection. In general, non-White patients with ESKD have less access to transplantation, especially living donor transplantation. We examined long-term outcomes of patients with ADPKD-ESKD by self-reported race, with attention to the trajectory of Estimated Post-Transplant Survival (EPTS) scores over time. Methods: United Network for Organ Sharing Standard Transplant Analysis and Research files were used to identify 32,611 ADPKD transplant recipients between January 2000 and December 2022. EPTS scores were calculated from the date of waitlisting until transplantation occurred. Cumulative incidences of living and deceased transplantation were calculated and plotted. Cox models were made for graft failure and death, and a subdistribution hazards model for graft failure accounted for death as a competing outcome, with adjustment for patient, donor, and transplant factors. Results: Compared with White patients with ADPKD, all other groups had more dialysis years, more delayed graft function, and fewer living and preemptive transplants; mean EPTS scores were lower in Black and Hispanic patients at each time point on the waitlist. However, EPTS scores at the time of transplant was less likely to be <20% in Black and Hispanic patients because of longer waiting time. Black patients had a significantly higher risk of graft failure with death as competing risk compared with White patients. Asian and Hispanic patients had similar graft survivals but better patient survival compared with White patients. Conclusions: Waitlist experience, allograft quality, and post-transplant outcomes of patients with ADPKD are influenced by patient race.
- Open Access
- 28 October 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (12) , 1922-1924
Building a Physician/Advanced Practice Provider Partnership for Inpatient Dialysis Care
An abstract is unavailable. This article is available as a PDF only.
- 28 October 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (12) , 1922-1924
Open AccessBuilding a Physician/Advanced Practice Provider Partnership for Inpatient Dialysis Care
An abstract is unavailable. This article is available as a PDF only.
- 1 July 2022
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 17 (7) , 976-985
Health Disparities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States
Background and objectives: Autosomal dominant polycystic kidney disease (ADPKD) occurs at conception and is often diagnosed decades prior to kidney failure. Nephrology care and transplantation access should be independent of race and ethnicity. However, institutional racism and barriers to health care may affect patient outcomes in ADPKD. We sought to ascertain the effect of health disparities on outcomes in ADPKD by examining age at onset of kidney failure and access to preemptive transplantation and transplantation after dialysis initiation. Design, setting, participants, & measurements: Retrospective cohort analyses of adults with ADPKD in the United States Renal Data System from January 2000 to June 2018 were merged to US Census income data and evaluated by self-reported race and ethnicity. Age at kidney failure was analyzed in a linear model, and transplant rates before and after dialysis initiation were analyzed in logistic and proportional hazards models in Black and Hispanic patients with ADPKD compared with White patients with ADPKD. Results: A total of 41,485 patients with ADPKD were followed for a median of 25 (interquartile range, 5–54) months. Mean age was 56±12 years; 46% were women, 13% were Black, and 10% were Hispanic. Mean ages at kidney failure were 55±13, 53±12, and 57±12 years for Black patients, Hispanic patients, and White patients, respectively. Odds ratios for preemptive transplant were 0.33 (95% confidence interval, 0.29 to 0.38) for Black patients and 0.50 (95% confidence interval, 0.44 to 0.56) for Hispanic patients compared with White patients. Transplant after dialysis initiation was 0.61 (95% confidence interval, 0.58 to 0.64) for Black patients and 0.78 (95% confidence interval, 0.74 to 0.83) for Hispanic patients. Conclusions: Black and Hispanic patients with ADPKD reach kidney failure earlier and are less likely to receive a kidney transplant preemptively and after initiating dialysis compared with White patients with ADPKD.
- 1 July 2022
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 17 (7) , 976-985
Health Disparities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States
Background and objectives: Autosomal dominant polycystic kidney disease (ADPKD) occurs at conception and is often diagnosed decades prior to kidney failure. Nephrology care and transplantation access should be independent of race and ethnicity. However, institutional racism and barriers to health care may affect patient outcomes in ADPKD. We sought to ascertain the effect of health disparities on outcomes in ADPKD by examining age at onset of kidney failure and access to preemptive transplantation and transplantation after dialysis initiation. Design, setting, participants, & measurements: Retrospective cohort analyses of adults with ADPKD in the United States Renal Data System from January 2000 to June 2018 were merged to US Census income data and evaluated by self-reported race and ethnicity. Age at kidney failure was analyzed in a linear model, and transplant rates before and after dialysis initiation were analyzed in logistic and proportional hazards models in Black and Hispanic patients with ADPKD compared with White patients with ADPKD. Results: A total of 41,485 patients with ADPKD were followed for a median of 25 (interquartile range, 5–54) months. Mean age was 56±12 years; 46% were women, 13% were Black, and 10% were Hispanic. Mean ages at kidney failure were 55±13, 53±12, and 57±12 years for Black patients, Hispanic patients, and White patients, respectively. Odds ratios for preemptive transplant were 0.33 (95% confidence interval, 0.29 to 0.38) for Black patients and 0.50 (95% confidence interval, 0.44 to 0.56) for Hispanic patients compared with White patients. Transplant after dialysis initiation was 0.61 (95% confidence interval, 0.58 to 0.64) for Black patients and 0.78 (95% confidence interval, 0.74 to 0.83) for Hispanic patients. Conclusions: Black and Hispanic patients with ADPKD reach kidney failure earlier and are less likely to receive a kidney transplant preemptively and after initiating dialysis compared with White patients with ADPKD.
- 23 June 2022
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 53 (7) , 534-541
Utilization of Cystatin C in the Outpatient Setting
Introduction: Serum creatinine is the traditional biomarker for estimating glomerular filtration rate (eGFR). Cystatin C is an alternative biomarker for which estimating equations exist. The use of cystatin C testing, and the interrelationships among the recently revised Chronic Kidney Disease Epidemiology (CKD-EPI) 2021 estimating equations, was evaluated in a national outpatient laboratory dataset. Methods: Cystatin C results reported on adults between November 2011 and June 2018 by Laboratory Corporation of America Holdings were examined, with classification of ordering providers and diagnostic codes. Updated eGFR results were calculated using the CKD-EPI 2021 equations for each sample with both cystatin C and creatinine values available. The Spearman correlation coefficients were calculated. Reclassification at clinically relevant cut-off values was examined. Results: There were 87,803 serum cystatin C levels among 55,360 patients; mean age 58 ± 17 years; 50% women. Cystatin C usage increased over time and was ordered for many indications. Among 73,367 samples with simultaneous creatinine and cystatin C, r = 0.84 between eGFR-creatinine and eGFR-cystatin. Correlations of eGFR-creatinine, eGFR-cystatin, and the averaged result of the two equations to the new combined equation were r = 0.94, r = 0.97, and r = 0.998, respectively (p < 0.001 for all). Use of combined/averaged equations tended to result in a higher eGFR and upclassification, compared to eGFR-creatinine. Conclusion/Discussion: Use of Cystatin C is increasing and has moved beyond the nephrology community and the original indications from the 2012 KDIGO guidelines. Community utilization of cystatin C measurement is likely to expand, and understanding of the relationships between estimating equations will help clinicians optimize their use in the outpatient setting.
- 23 June 2022
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 53 (7) , 534-541
Utilization of Cystatin C in the Outpatient Setting
Introduction: Serum creatinine is the traditional biomarker for estimating glomerular filtration rate (eGFR). Cystatin C is an alternative biomarker for which estimating equations exist. The use of cystatin C testing, and the interrelationships among the recently revised Chronic Kidney Disease Epidemiology (CKD-EPI) 2021 estimating equations, was evaluated in a national outpatient laboratory dataset. Methods: Cystatin C results reported on adults between November 2011 and June 2018 by Laboratory Corporation of America Holdings were examined, with classification of ordering providers and diagnostic codes. Updated eGFR results were calculated using the CKD-EPI 2021 equations for each sample with both cystatin C and creatinine values available. The Spearman correlation coefficients were calculated. Reclassification at clinically relevant cut-off values was examined. Results: There were 87,803 serum cystatin C levels among 55,360 patients; mean age 58 ± 17 years; 50% women. Cystatin C usage increased over time and was ordered for many indications. Among 73,367 samples with simultaneous creatinine and cystatin C, r = 0.84 between eGFR-creatinine and eGFR-cystatin. Correlations of eGFR-creatinine, eGFR-cystatin, and the averaged result of the two equations to the new combined equation were r = 0.94, r = 0.97, and r = 0.998, respectively (p < 0.001 for all). Use of combined/averaged equations tended to result in a higher eGFR and upclassification, compared to eGFR-creatinine. Conclusion/Discussion: Use of Cystatin C is increasing and has moved beyond the nephrology community and the original indications from the 2012 KDIGO guidelines. Community utilization of cystatin C measurement is likely to expand, and understanding of the relationships between estimating equations will help clinicians optimize their use in the outpatient setting.